Polyrizon Ltd. has announced positive in-vitro results for its PL-16 Viral Blocker, a proprietary intranasal gel designed to protect against respiratory viruses. The research demonstrated that the formulation provides broad-spectrum viral blocking, including strong protection against the H1N1 influenza virus, by creating a reversible physical barrier on the nasal mucosa. This non-pharmacological mechanism traps and neutralizes viruses mechanically without cytotoxic effects, supporting the product's safety and efficacy. The company indicated that future development will include clinical studies, pending regulatory approvals, but has not stated whether these research results have been or will be presented at a scientific conference or publication.